Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer

Cancer Biology and Therapy

Volumn 17, Issue 7, 2016, Pages 751-759

  Sunakawa, Yu ^a,b   Yang, Dongyun ^a   Moran, Miriana ^c   Astrow, Stephanie H ^c   Tsuji, Akihito ^d   Stephens, Craig ^c   Zhang, Wu ^a   Cao, Shu ^a   Takahashi, Takehiro ^e   Denda, Tadamichi ^f   Shimada, Ken ^g   Kochi, Mitsugu ^h   Nakamura, Masato ⁱ   Kotaka, Masahito ^j   Segawa, Yoshihiko ^k   Masuishi, Toshiki ^l   Takeuchi, Masahiro ^m   Fujii, Masashi ^h   Nakajima, Toshifusa ⁿ   Ichikawa, Wataru ^o   Lenz, Heinz Josef ^a   more..

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b SHOWA UNIVERSITY NORTHERN YOKOHAMA HOSPITAL   (Japan)

^c Response Genetics Inc   (United States)

^d KAGAWA UNIVERSITY HOSPITAL   (Japan)

^e SHOWA UNIVERSITY HOSPITAL   (Japan)

^f CHIBA CANCER CENTER   (Japan)

^g Showa University Koto Hospital   (Japan)

^h NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ Aizawa Hospital   (Japan)

^j National Hospital Organization   (Japan)

^k SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^l TSUCHIURA KYODO GENERAL HOSPITAL   (Japan)

^m KITASATO UNIVERSITY   (Japan)

ⁿ Japan Clinical Cancer Research Organization   (Japan)

^o SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

more..

Author keywords

Amphiregulin; cetuximab; colorectal cancer; EGFR; EGFR gene copy number

Indexed keywords

AMPHIREGULIN; CETUXIMAB; EPIREGULIN; FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; OXALIPLATIN; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CA SSR1 GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; DNA POLYMORPHISM; FEMALE; GENE; GENE DOSAGE; GENE EXPRESSION; GENOTYPE; HUMAN; HUMAN TISSUE; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; ONCOGENE K RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); POST TREATMENT SURVIVAL; PROGRESSION FREE SURVIVAL; SKIN TOXICITY; COLORECTAL NEOPLASMS; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CETUXIMAB; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84969651394     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2016.1178426     Document Type: Article

References (50)

1. G.Galizia, E.Lieto, F.De Vita, M.Orditura, P.Castellano, T.Troiani, V.Imperatore, F.Ciardiello. Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene 2007; 26:3654-60; PMID:17530019; http://dx.doi.org/10.1038/sj.onc.1210381
2. E.Van Cutsem, C.H.Kohne, E.Hitre, J.Zaluski, C.R.Chang Chien, A.Makhson, G.D'Haens, T.Pinter, R.Lim, G.Bodoky, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Eng J Med 2009; 360:1408-17; PMID:19339720; http://dx.doi.org/10.1056/NEJMoa0805019
3. C.Bokemeyer, I.Bondarenko, J.T.Hartmann, F.de Braud, G.Schuch, A.Zubel, I.Celik, M.Schlichting, P.Koralewski. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011; 22:1535-46; PMID:21228335; http://dx.doi.org/10.1093/annonc/mdq632
4. R.G.Amado, M.Wolf, M.Peeters, E.Van Cutsem, S.Siena, D.J.Freeman, T.Juan, R.Sikorski, S.Suggs, R.Radinsky, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626-34; PMID:18316791; http://dx.doi.org/10.1200/JCO.2007.14.7116
5. C.S.Karapetis, S.Khambata-Ford, D.J.Jonker, C.J.O'Callaghan, D.Tu, N.C.Tebbutt, R.J.Simes, H.Chalchal, J.D.Shapiro, S.Robitaille, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Eng J Med 2008; 359:1757-65; PMID:18946061; http://dx.doi.org/10.1056/NEJMoa0804385
6. C.J.Allegra, J.M.Jessup, M.R.Somerfield, S.R.Hamilton, E.H.Hammond, D.F.Hayes, P.K.McAllister, R.F.Morton, R.L.Schilsky. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27:2091-6; PMID:19188670; http://dx.doi.org/10.1200/JCO.2009.21.9170
7. I.J.Dahabreh, T.Terasawa, P.J.Castaldi, T.A.Trikalinos. Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med 2011; 154:37-49; PMID:21200037; http://dx.doi.org/10.7326/0003-4819-154-1-201101040-00006
8. J.Y.Douillard, K.S.Oliner, S.Siena, J.Tabernero, R.Burkes, M.Barugel, Y.Humblet, G.Bodoky, D.Cunningham, J.Jassem, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Eng J Med 2013; 369:1023-34; PMID:24024839; http://dx.doi.org/10.1056/NEJMoa1305275
9. V.Heinemann, L.F.von Weikersthal, T.Decker, A.Kiani, U.Vehling-Kaiser, S.E.Al-Batran, T.Heintges, C.Lerchenmuller, C.Kahl, G.Seipelt, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15:1065-75; PMID:25088940; http://dx.doi.org/10.1016/S1470-2045(14)70330-4
10. H.Lenz, D.Niedzwiecki, F.Innocenti, C.Blanke, M.R.Mahony, B.H.O'Neil, J.E.Shaw, B.Polite, H.Hochster, J.Atkins, et al. 501OCALGB/SWOG 80405: PHASE III TRIAL OF IRINOTECAN/5-FU/LEUCOVORIN (FOLFIRI) OR OXALIPLATIN/5-FU/LEUCOVORIN (MFOLFOX6) WITH BEVACIZUMAB (BV) OR CETUXIMAB (CET) FOR PATIENTS (PTS) WITH EXPANDED RAS ANALYSES UNTREATED METASTATIC ADENOCARCINOMA OF THE COLON OR RECTUM (MCRC). Ann Oncol 2014; 25; PMID:25411415; http://dx.doi.org/10.1093/annonc/mdu438.13
11. M.Moroni, S.Veronese, S.Benvenuti, G.Marrapese, A.Sartore-Bianchi, F.Di Nicolantonio, M.Gambacorta, S.Siena, A.Bardelli. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6:279-86; PMID:15863375; http://dx.doi.org/10.1016/S1470-2045(05)70102-9
12. M.Frattini, P.Saletti, E.Romagnani, V.Martin, F.Molinari, M.Ghisletta, A.Camponovo, L.L.Etienne, F.Cavalli, L.Mazzucchelli. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007; 97:1139-45; PMID:17940504; http://dx.doi.org/10.1038/sj.bjc.6604009
13. S.Khambata-Ford, C.R.Garrett, N.J.Meropol, M.Basik, C.T.Harbison, S.Wu, T.W.Wong, X.Huang, C.H.Takimoto, A.K.Godwin, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25:3230-7; PMID:17664471; http://dx.doi.org/10.1200/JCO.2006.10.5437
14. Z.Saridaki, M.Tzardi, C.Papadaki, M.Sfakianaki, F.Pega, A.Kalikaki, E.Tsakalaki, M.Trypaki, I.Messaritakis, E.Stathopoulos, et al. Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in >/= 2 line cetuximab-based therapy of colorectal cancer patients. PloS One 2011; 6:e15980; PMID:21283802; http://dx.doi.org/10.1371/journal.pone.0015980
15. G.Pentheroudakis, V.Kotoula, W.De Roock, G.Kouvatseas, P.Papakostas, T.Makatsoris, D.Papamichael, I.Xanthakis, J.Sgouros, D.Televantou, et al. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC cancer 2013; 13:49; PMID:23374602; http://dx.doi.org/10.1186/1471-2407-13-49
16. B.Jacobs, W.De Roock, H.Piessevaux, R.Van Oirbeek, B.Biesmans, J.De Schutter, S.Fieuws, J.Vandesompele, M.Peeters, J.L.Van Laethem, et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 2009; 27:5068-74; PMID:19738126; http://dx.doi.org/10.1200/JCO.2008.21.3744
17. F.Loupakis, C.Cremolini, A.Fioravanti, P.Orlandi, L.Salvatore, G.Masi, M.Schirripa, T.Di Desidero, C.Antoniotti, B.Canu, et al. EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. Targeted Oncol 2014; 9:205-14; PMID:23821377; http://dx.doi.org/10.1007/s11523-013-0284-7
18. F.Di Fiore, R.Sesboue, P.Michel, J.C.Sabourin, T.Frebourg. Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. Br J Cancer 2010; 103:1765-72; PMID:21139621; http://dx.doi.org/10.1038/sj.bjc.6606008
19. Y.Yarden. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37 Suppl 4:S3-8; PMID:11597398; http://dx.doi.org/10.1016/S0959-8049(01)00230-1
20. N.E.Hynes, H.A.Lane. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5:341-54; PMID:15864276; http://dx.doi.org/10.1038/nrc1609
21. M.Scaltriti, J.Baselga. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006; 12:5268-72; PMID:17000658; http://dx.doi.org/10.1158/1078-0432.CCR-05-1554
22. S.Stintzing, A.Jung, C.Kapaun, J.Reiche, D.P.Modest, C.A.Giessen, U.Vehling-Kaiser, M.Stauch, H.Hass, L.Fischer von Weikersthal, et al. Ligand expression of the EGFR ligands amphiregulin, epiregulin, and amplification of the EGFR gene to predict for treatment efficacy in KRAS wild-type mCRC patients treated with cetuximab plus CAPIRI and CAPOX: Analysis of the randomized AIO CRC-0104 trial. ASCO Meeting Abstracts 2012; 30:3519.
23. J.F.Seligmann, F.Elliott, S.D.Richman, B.Jacobs, G.Hemmings, S.Brown, J.H.Barrett, S.Tejpar, P.Quirke, M.T.Seymour. Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer. JAMA Oncol 2016; PMID:26867820; http://dx.doi.org/10.1001/jamaoncol.2015.6065
24. A.Stahler, V.Heinemann, C.Giessen-Jung, A.Crispin, A.Schalhorn, S.Stintzing, L.Fischer von Weikersthal, U.Vehling-Kaiser, M.Stauch, D.Quietzsch, et al. Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial). Int J Cancer 2016; 138:739-46; PMID:26284333; http://dx.doi.org/10.1002/ijc.29807
25. J.L.Yang, X.J.Qu, P.J.Russell, D.Goldstein. Regulation of epidermal growth factor receptor in human colon cancer cell lines by interferon alpha. Gut 2004; 53:123-9; PMID:14684586; http://dx.doi.org/10.1136/gut.53.1.123
26. P.Matar, F.Rojo, R.Cassia, G.Moreno-Bueno, S.Di Cosimo, J.Tabernero, M.Guzman, S.Rodriguez, J.Arribas, J.Palacios, et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res 2004; 10:6487-501; PMID:15475436; http://dx.doi.org/10.1158/1078-0432.CCR-04-0870
27. P.Laurent-Puig, A.Cayre, G.Manceau, E.Buc, J.B.Bachet, T.Lecomte, P.Rougier, A.Lievre, B.Landi, V.Boige, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009; 27:5924-30; PMID:19884556; http://dx.doi.org/10.1200/JCO.2008.21.6796
28. A.Sartore-Bianchi, M.Moroni, S.Veronese, C.Carnaghi, E.Bajetta, G.Luppi, A.Sobrero, C.Barone, S.Cascinu, G.Colucci, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007; 25:3238-45; PMID:17664472; http://dx.doi.org/10.1200/JCO.2007.11.5956
29. F.Cappuzzo, G.Finocchiaro, E.Rossi, P.A.Janne, C.Carnaghi, C.Calandri, K.Bencardino, C.Ligorio, F.Ciardiello, T.Pressiani, et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 2008; 19:717-23; PMID:17974556; http://dx.doi.org/10.1093/annonc/mdm492
30. M.Scartozzi, I.Bearzi, A.Mandolesi, C.Pierantoni, F.Loupakis, A.Zaniboni, F.Negri, A.Quadri, F.Zorzi, E.Galizia, et al. Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. BMC Cancer 2009; 9:303; PMID:19712476; http://dx.doi.org/10.1186/1471-2407-9-303
31. N.Personeni, S.Fieuws, H.Piessevaux, G.De Hertogh, J.De Schutter, B.Biesmans, W.De Roock, A.Capoen, M.Debiec-Rychter, J.L.Van Laethem, et al. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clinical Cancer Res 2008; 14:5869-76; PMID:18794099; http://dx.doi.org/10.1158/1078-0432.CCR-08-0449
32. F.Perrone, A.Lampis, M.Orsenigo, M.Di Bartolomeo, A.Gevorgyan, M.Losa, M.Frattini, C.Riva, S.Andreola, E.Bajetta, et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 2009; 20:84-90; PMID:18669866; http://dx.doi.org/10.1093/annonc/mdn541
33. E.Razis, E.Briasoulis, E.Vrettou, D.V.Skarlos, D.Papamichael, I.Kostopoulos, E.Samantas, I.Xanthakis, M.Bobos, E.Galanidi, et al. Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study. BMC cancer 2008; 8:234; PMID:18700047; http://dx.doi.org/10.1186/1471-2407-8-234
34. S.Stintzing, C.Kapaun, R.P.Laubender, A.Jung, J.Neumann, D.P.Modest, C.Giessen, N.Moosmann, A.Wollenberg, T.Kirchner, et al. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Int J Cancer 2013; 132:236-45; PMID:22644776; http://dx.doi.org/10.1002/ijc.27654
35. M.Miyazaki, T.Furuya, A.Shiraki, T.Sato, A.Oga, K.Sasaki. The relationship of DNA ploidy to chromosomal instability in primary human colorectal cancers. Cancer Res 1999; 59:5283-5; PMID:10537310
36. A.Ooi, T.Takehana, X.Li, S.Suzuki, K.Kunitomo, H.Iino, H.Fujii, Y.Takeda, Y.Dobashi. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol 2004; 17:895-904; PMID:15143334; http://dx.doi.org/10.1038/modpathol.3800137
37. F.Graziano, A.Ruzzo, F.Loupakis, E.Canestrari, D.Santini, V.Catalano, R.Bisonni, U.Torresi, I.Floriani, G.Schiavon, et al. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J Clin Oncol 2008; 26:1427-34; PMID:18349392; http://dx.doi.org/10.1200/JCO.2007.12.4602
38. J.Pander, H.Gelderblom, N.F.Antonini, J.Tol, J.H.van Krieken, T.van der Straaten, C.J.Punt, H.J.Guchelaar. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. Eur J Cancer 2010; 46:1829-34; PMID:20418097; http://dx.doi.org/10.1016/j.ejca.2010.03.017
39. G.Lurje, F.Nagashima, W.Zhang, D.Yang, H.M.Chang, M.A.Gordon, A.El-Khoueiry, H.Husain, P.M.Wilson, R.D.Ladner, et al. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin Cancer Res 2008; 14:7884-95; PMID:19047118; http://dx.doi.org/10.1158/1078-0432.CCR-07-5165
40. J.H.Park, S.W.Han, D.Y.Oh, S.A.Im, S.Y.Jeong, K.J.Park, T.Y.Kim, Y.J.Bang, J.G.Park. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer. Cancer Chemother Pharmacol 2011; 68:1045-55; PMID:21340604; http://dx.doi.org/10.1007/s00280-011-1586-z
41. L.Dahan, E.Norguet, M.C.Etienne-Grimaldi, J.L.Formento, M.Gasmi, I.Nanni, J.Gaudart, S.Garcia, L.Ouafik, J.F.Seitz, et al. Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer. BMC Cancer 2011; 11:496; PMID:22117530; http://dx.doi.org/10.1186/1471-2407-11-496
42. W.Liu, F.Innocenti, P.Chen, S.Das, E.H.Cook, Jr., M.J.Ratain. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res 2003; 9:1009-12; PMID:12631599
43. J.Tol, J.R.Dijkstra, M.Klomp, S.Teerenstra, M.Dommerholt, M.E.Vink-Borger, P.H.van Cleef, J.H.van Krieken, C.J.Punt, I.D.Nagtegaal. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer 2010; 46:1997-2009; PMID:20413299; http://dx.doi.org/10.1016/j.ejca.2010.03.036
44. E.Van Cutsem, H.J.Lenz, C.H.Kohne, V.Heinemann, S.Tejpar, I.Melezinek, F.Beier, C.Stroh, P.Rougier, J.H.van Krieken, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 2015; 33:692-700; PMID:25605843; http://dx.doi.org/10.1200/JCO.2014.59.4812
45. V.De Vriendt, W.De Roock, A.F.Di Narzo, S.Tian, B.Biesmans, B.Jacobs, E.Budinska, X.Sagaert, S.Rossi, G.D'Ario, et al. DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype. Biomarkers 2013; 18:516-24; PMID:23875912; http://dx.doi.org/10.3109/1354750X.2013.819038
46. C.Oliveras-Ferraros, A.Vazquez-Martin, S.Cufi, B.Queralt, L.Baez, R.Guardeno, X.Hernandez-Yague, B.Martin-Castillo, J.Brunet, J.A.Menendez. Stem cell property epithelial-to-mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux) efficacy in KRAS wild-type tumor cells. J Cell Biochem 2011; 112:10-29; PMID:21104905; http://dx.doi.org/10.1002/jcb.22952
47. M.L.Amador, D.Oppenheimer, S.Perea, A.Maitra, G.Cusatis, C.Iacobuzio-Donahue, S.D.Baker, R.Ashfaq, C.Takimoto, A.Forastiere, et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 2004; 64:9139-43; PMID:15604284; http://dx.doi.org/10.1158/0008-5472.CAN-04-1036
48. R.Miller, D.Siegmund. Maximally selected chi square statistics. Biometrics 1982; 38:1011-16; http://dx.doi.org/10.2307/2529881
49. J.Halpern. Maximally selected chi square statistics for small samples. Biometrics 1982; 38:1017-23; http://dx.doi.org/10.2307/2529882
50. D.Vallbohmer, W.Zhang, M.Gordon, D.Y.Yang, J.Yun, O.A.Press, K.E.Rhodes, A.E.Sherrod, S.Iqbal, K.D.Danenberg, et al. Molecular determinants of cetuximab efficacy. J Clin Oncol 2005; 23:3536-44; PMID:15908664; http://dx.doi.org/10.1200/JCO.2005.09.100